AGIO vs. GPCR, EVO, SNDX, AMRX, GLPG, CPRX, SDGR, HRMY, RNA, and NAMS
Should you be buying Agios Pharmaceuticals stock or one of its competitors? The main competitors of Agios Pharmaceuticals include Structure Therapeutics (GPCR), Evotec (EVO), Syndax Pharmaceuticals (SNDX), Amneal Pharmaceuticals (AMRX), Galapagos (GLPG), Catalyst Pharmaceuticals (CPRX), Schrödinger (SDGR), Harmony Biosciences (HRMY), Avidity Biosciences (RNA), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical preparations" industry.
Agios Pharmaceuticals (NASDAQ:AGIO) and Structure Therapeutics (NASDAQ:GPCR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, community ranking, institutional ownership, media sentiment, risk, valuation, earnings and dividends.
91.8% of Structure Therapeutics shares are owned by institutional investors. 4.2% of Agios Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Structure Therapeutics has lower revenue, but higher earnings than Agios Pharmaceuticals. Structure Therapeutics is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Agios Pharmaceuticals currently has a consensus price target of $35.00, indicating a potential upside of 1.33%. Structure Therapeutics has a consensus price target of $85.71, indicating a potential upside of 118.16%. Given Structure Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Structure Therapeutics is more favorable than Agios Pharmaceuticals.
Structure Therapeutics has a net margin of 0.00% compared to Agios Pharmaceuticals' net margin of -1,199.26%. Structure Therapeutics' return on equity of -32.69% beat Agios Pharmaceuticals' return on equity.
In the previous week, Agios Pharmaceuticals had 8 more articles in the media than Structure Therapeutics. MarketBeat recorded 14 mentions for Agios Pharmaceuticals and 6 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 0.63 beat Agios Pharmaceuticals' score of 0.04 indicating that Structure Therapeutics is being referred to more favorably in the news media.
Agios Pharmaceuticals received 464 more outperform votes than Structure Therapeutics when rated by MarketBeat users. However, 77.78% of users gave Structure Therapeutics an outperform vote while only 67.80% of users gave Agios Pharmaceuticals an outperform vote.
Summary
Structure Therapeutics beats Agios Pharmaceuticals on 11 of the 16 factors compared between the two stocks.
Get Agios Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AGIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Agios Pharmaceuticals Competitors List
Related Companies and Tools
